DNA binding to an anticancer organo-ruthenium complex
- PMID: 20961087
- DOI: 10.1021/jp1044783
DNA binding to an anticancer organo-ruthenium complex
Abstract
Because many anticancer drugs interact with DNA, the determination of their association constants to DNA is essential for quantifying their mechanisms of action. The interactions between a new ruthenium-derived compound [ruthenium(phenanthroline)(κ-C,N-(2-phenyl-pyridine)(NCMe)(2)]PF(6), called RDC11] and DNA are studied using different techniques. Fluorescent experiments are used to determine the association and dissociation constants under different salt concentrations. The binding is shown to be reversible and noncovalent. The association constants vary from 1.5 × 10(6) M(-1) to 2.9 × 10(3) M(-1) when increasing the sodium concentration from 0.1 to 200 mM. Single-molecule stretching methods are used to study the interaction of RDC with longer DNA strands (8.6 kbp home-built dimer of pBR322). The affinities of RDC with DNA under different loads are obtained using McGhee and von Hippel analysis. The affinity constant and thermodynamic parameters are in good agreement with the values found in the literature and lead to the conclusion that this molecule intercalates dsDNA.
Similar articles
-
DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.Biochemistry. 2003 Oct 7;42(39):11544-54. doi: 10.1021/bi034933u. Biochemistry. 2003. PMID: 14516206
-
Binding of organometallic ruthenium(II) anticancer compounds to nucleobases: a computational study.J Phys Chem A. 2009 Oct 29;113(43):11888-97. doi: 10.1021/jp903237w. J Phys Chem A. 2009. PMID: 19791792
-
Mechanism of interstrand migration of organoruthenium anticancer complexes within a DNA duplex.Metallomics. 2012 Feb;4(2):139-48. doi: 10.1039/c2mt00162d. Epub 2012 Jan 20. Metallomics. 2012. PMID: 22262368
-
Interactions of metallopharmaceuticals with DNA.Met Ions Biol Syst. 1996;32:727-80. Met Ions Biol Syst. 1996. PMID: 8640536 Review. No abstract available.
-
Polynuclear ruthenium, osmium and gold complexes. The quest for innovative anticancer chemotherapeutics.Curr Top Med Chem. 2011;11(21):2688-702. doi: 10.2174/156802611798040769. Curr Top Med Chem. 2011. PMID: 22039871 Review.
Cited by
-
DNA molecular recognition and cellular selectivity of anticancer metal(II) complexes of ethylenediaminediacetate and phenanthroline: multiple targets.J Biol Inorg Chem. 2012 Jan;17(1):57-69. doi: 10.1007/s00775-011-0829-0. Epub 2011 Aug 11. J Biol Inorg Chem. 2012. PMID: 21833656
-
Synthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexes.Dalton Trans. 2016 Apr 28;45(16):7049-66. doi: 10.1039/c6dt00465b. Dalton Trans. 2016. PMID: 26990859 Free PMC article.
-
Flexibility of short ds-DNA intercalated by a dipyridophenazine ligand.Front Chem. 2015 Apr 16;3:25. doi: 10.3389/fchem.2015.00025. eCollection 2015. Front Chem. 2015. PMID: 25932461 Free PMC article.
-
Synthesis, structure, photophysical and electrochemical properties of Ru(TFA)(CO)(PPh3)2(L) (L=2-phenylpyridine, 2-p-tolylpyridine) and Ru(CO)(PPhMe2)2(L)(L') (L= TFA, H) (L'= bipyridine, L'= 4,4'-dimethylbipyridine) relationships between ancillary ligand structure and luminescent properties.J Organomet Chem. 2017 Nov 1;849-#008211850:306-314. doi: 10.1016/j.jorganchem.2017.03.026. Epub 2017 Mar 16. J Organomet Chem. 2017. PMID: 32461702 Free PMC article.
-
N-Heterocyclic Carbene-Platinum Complexes Featuring an Anthracenyl Moiety: Anti-Cancer Activity and DNA Interaction.Int J Mol Sci. 2019 Aug 27;20(17):4198. doi: 10.3390/ijms20174198. Int J Mol Sci. 2019. PMID: 31461928 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources